Sernova Team Participates at Key US Life Sciences Event: 2014 BIO International Convention, San Diego
24 6월 2014 - 7:00PM
Marketwired
Sernova Team Participates at Key US Life Sciences Event: 2014 BIO
International Convention, San Diego
LONDON, ONTARIO--(Marketwired - Jun 24, 2014) - Sernova Corp.
(TSX-VENTURE:SVA), a clinical stage company developing disruptive
medical technologies for the long-term treatment of chronic
diseases such as diabetes and haemophilia announced today that it
is participating at the US BIO International Convention in San
Diego, June 23-26th.
"This is an excellent occasion for Sernova to present to
international institutions, pharma and potential collaborators to
update attendees on our progress and pipeline," remarked Dr. Philip
Toleikis, President and CEO.
The convention is an important annual business development forum
which allows high-level executives and influential decision makers
attending BIO to liaise with key players in the industry, form
partnerships, and evaluate emerging technologies.
"Sernova's entire business development team is attending and has
numerous one-on-one meetings booked to discuss its proprietary
platform - many important collaborations mark their origins to
BIO," remarked Kevin Egan, chair of Sernova's Business Advisory
Board.
About
Sernova
Sernova Corp. is a clinical stage regenerative medicine company
developing medical technologies for the treatment of chronic
debilitating metabolic diseases such as diabetes, blood disorders
including haemophilia and other diseases treated through
replacement of proteins or hormones missing or in short supply
within the body. Sernova is developing the Cell Pouch™, an
implantable medical device for therapeutic cells (donor, xenogeneic
or stem cells) which then release proteins and/or hormones as
required. The therapeutic cells are protected from immune attack by
Sernova's proprietary technologies.
Forward-Looking Information
This release may contain forward-looking statements.
Forward-looking statements are statements that are not historical
facts and are generally, but not always, identified by the words
"expects", "plans", "anticipates", "believes", "intends",
"estimates", "projects", "potential" and similar expressions, or
that events or conditions "will", "would", "may", "could" or
"should" occur. Although Sernova believes the expectations
expressed in such forward-looking statements are based on
reasonable assumptions, such statements are not guarantees of
future performance and actual results may differ materially from
those in forward-looking statements. Forward-looking statements are
based on the beliefs, estimates and opinions of Sernova's
management on the date such statements were made. Sernova expressly
disclaims any intention or obligation to update or revise any
forward-looking statements whether as a result of new information,
future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Sernova Corp.Philip Toleikis, Ph.D.President and CEO(604)
961-2939philip.toleikis@sernova.com /
info@sernova.comwww.sernova.comRay Matthews & AssociatesRay
Matthews(604) 818-7778www.raymatthews.ca
Sernova (TSXV:SVA)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Sernova (TSXV:SVA)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024